TG Therapeutics (TGTX) just delivered third quarter 2026 results that combined robust revenue with much slimmer profits. The business also raised full year revenue guidance to about US$1b, which sharpened investor focus. The strong third quarter report and higher 2026 revenue outlook landed on a stock that has already been on a powerful run, with a 30 day share price return of 16.06% and a year to date share price gain of 119.47% at a recent US$64.26. The 3 year total shareholder return of...
Check out my latest article. I specified that I had call options on TG Therapeutics (TGTX)Check out this chart showing how stock valuation has been...
Shares raced through a buy zone but are range of an alternate entry.
Motley Fool Press Release.
(TGTX) on Monday reported third-quarter earnings of $55.On a per-share basis, the Morrisville, North Carolina-based company said it had net income of 35 cents.
Ebay, Quest Diagnostics, Fastenal, Chubb are around buy points after earnings.
Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.
Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.
TG Therapeutics, Inc. has scheduled multiple data presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), including a late-breaking oral session on initial Phase 1 results for azer-cel, an allogeneic CD19-directed CAR T-cell therapy in primary progressive multiple sclerosis, alongside extensive new clinical and real-world analyses of BRIUMVI across relapsing multiple sclerosis and other autoimmune settings. This concentrated release of early azer-cel findings and long-term...
TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. Spea
TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Therapeutics has leaned into stronger momentum, with a 30-day share price return of 12.36% and a year-to-date share price return of 92.86%. The one-year total shareholder return of 73.17% and roughly 5x three-year total shareholder return suggest earlier buyers...
TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.
Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ETNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held on September 9 - 11, 2026. The fireside chat is scheduled to take place on Wednesday, September 9, 2026, at 11:30am ET. A live webcast of the fireside chat will be available on the Eve
Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.
The multiple sclerosis biotech has topped an early entry and is near a breakout.
TGTX stock is recovering from an earnings sell-off in early August. building a base. The biotech stock is testing a key moving average.
TG Therapeutics stock rips higher on takeover speculation. But should you chase the momentum on Friday? Let’s find out!
This is the newest page. Registered accounts read further back.